Adaptin Bio (APTN) Free Cash Flow (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Free Cash Flow data on file, last reported at -$596298.0 in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 73.85% year-over-year to -$596298.0; the trailing twelve-month figure through Mar 2026 stood at -$3.1 million (down 8.98% YoY), and the FY2025 full-year result was -$4.8 million, down 635.87% from the prior year.
• Free Cash Flow grew to -$596298.0 in Q1 2026, from -$702876.0 in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $112653.0 in Q4 2024 to a low of -$2.3 million in Q1 2025.
• A 4-year average of -$608182.0 and a median of -$532357.0 in 2024 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow surged 293.07% in 2024 and sank 2441.81% in 2025, its largest moves.
• Tracing APTN's Free Cash Flow over 4 years: stood at -$58347.0 in 2023, then surged by 293.07% to $112653.0 in 2024, then sank by 723.93% to -$702876.0 in 2025, then grew by 15.16% to -$596298.0 in 2026.
• Business Quant data shows APTN's Free Cash Flow at -$596298.0 in Q1 2026, -$702876.0 in Q4 2025, and -$772430.0 in Q3 2025.